Let's advance your
therapeutic program.

Quantum-enhanced computational translational biology for therapeutic asset advancement.

Seven questions. No account required.

NDA & Initial Discussions

Collaborations & Partners

  • Southern Illinois University School of Medicine, Springfield
  • University of Missouri Health System, Columbia
  • WashU Medicine, St. Louis
  • University of Porto, Portugal
  • Indian Institute of Science (IISc), India
  • University Hospital Würzburg, Germany
Who we help

We help your therapeutic assets advance.

Academia

You already have

  • A therapeutic candidate
  • An antibody
  • An RNA construct
  • A nanoparticle
  • A promising biological mechanism

You need help moving it toward translation.

Small biotech

You already have

  • One lead asset
  • One therapeutic platform
  • One IND candidate

You need to answer whether it reaches the target tissue, why efficacy is inconsistent, where off-target toxicity may occur, and whether the formulation can improve.

Therapeutic Programs

Five strategic areas.

Selected where delivery, targeting, or off-target biology is the rate-limiting step.

  • Oncology

    Pancreatic · Triple-negative breast · Ovarian · Endometrial · Prostate · Pediatric · Hematologic

    Tumor-targeted delivery, tumor microenvironment, stromal penetration, intracellular delivery, organ-specific off-target effects.

  • Central Nervous System

    Alzheimer's · Parkinson's · Glioblastoma · ALS · Huntington's

    Blood-brain barrier penetration, neuroinflammation, protein aggregation, regional brain targeting.

  • Women's Health

    Endometriosis · Endometrial · Ovarian · Pelvic inflammatory disease

    Lesion-specific delivery, reproductive tissue targeting, inflammatory and hormonal microenvironments.

  • Kidney Diseases

    IgA nephropathy · CKD · Glomerular diseases

    Glomerular targeting, tubular exposure, transporter biology, kidney-specific off-target effects.

  • Infectious Diseases

    Tuberculosis · HIV · Vaccine-preventable · Tropical infections

    Intracellular delivery, tissue reservoirs, granuloma penetration, antimicrobial optimization.

Emerging programs

We also evaluate scientifically compelling programs outside these areas case by case, where computational modeling can accelerate translational research.

How we help

We sit between optimization and preclinical.

The stage where most programs fail quietly — and where computation is cheapest.

  1. Target Discovery
  2. Hit Discovery
  3. Lead Discovery
  4. Lead Optimization

QuanDruPlex

  • Drug Delivery
  • Tissue Targeting
  • Microenvironment
  • Off-target Effects
  • Biological Modifiers
  • Translational Modeling
  1. Preclinical
  2. IND
  3. Clinical
Technology

Quantum-enhanced computational translational biology.

We model biological systems, therapeutic delivery, tissue microenvironments, and organ-specific off-target interactions to accelerate safer medicines.

The stack

  1. Quantum-enhanced simulation
  2. Hybrid quantum-classical algorithms
  3. Biological modifier engine
  4. Microenvironment modeling
  5. Transport physics
  6. Mechanistic disease modeling
  7. Clinical digital twins

Platform modules

  • Molecular Modeling
  • Drug Delivery Modeling
  • Organ Distribution
  • Tissue Microenvironment
  • Transporter Biology
  • Protein Interaction Modeling
  • Extracellular Vesicles
  • Multi-omics Integration
  • Clinical Digital Twins
  • Mechanistic Disease Simulation
GUIDANCE™

Eight phases. Start where it matters.

Programs enter at the phase matching the limiting factor, then advance only as evidence justifies the next commitment.

  1. G

    Structural & Genomic Grounding

    Establish the molecular ground truth: structures, variants, and expression context for the target and its neighborhood.

  2. U

    Uptake & Delivery Modeling

    Model how the asset enters the relevant compartment, including formulation, permeability, and route of administration.

  3. I

    Interaction & Complex Mapping

    Quantum-enhanced sampling of binding, allostery, and multi-protein behavior beyond classical approximations.

  4. D

    Distribution & Tissue Targeting

    Organ- and tissue-level distribution modeling, including transporter-mediated gradients and residence time.

  5. A

    Adverse & Off-target Assessment

    Organ-specific off-target liability mapping to define the therapeutic window before animal spend.

  6. N

    Niche Microenvironment Simulation

    Simulate pH, hypoxia, matrix mechanics, and stromal barriers as they alter asset behavior in situ.

  7. C

    Candidate Optimization

    Iterate design proposals against the assembled model stack to improve exposure and selectivity.

  8. E

    Evidence Package & Translation

    Assemble a reviewer-ready computational evidence package for grants, diligence, or IND-enabling work.

Scientific Validation

Protected methods and patent portfolio.

Patent Family 1

Hybrid Quantum-Classical Systems for Drug Delivery Optimization

  • US provisional filed
  • PCT filed
Patent Family 2

Quantum Embedding Platform

  • US Utility Patent Filed
Collaborations

We work inside the academic pipeline.

  • Washington University in St. LouisFaculty collaboration
  • SIU School of MedicineAcademic partner
  • Portugal research networkInternational collaboration
  1. Academic drug discovery
  2. QuanDruPlex
  3. Validated therapeutic
  4. Pharmaceutical company
Publications

Methods in the open.

Working papers and methods notes. Peer-reviewed listings are added on acceptance.

  • 2026

    Quantum-enhanced sampling of transporter-mediated exposure gradients in solid tumor tissue

  • 2026

    Modeling barrier transit and endothelial efflux as a gating step for CNS therapeutic candidates

  • 2025

    GUIDANCE™: a phase-structured approach to computational de-risking of therapeutic assets

  • 2025

    Organ-resolved off-target liability mapping for early therapeutic window estimation

Full methods dossier available under CDA.

About

Boston deep-tech, at the interface of quantum computation and biology.

Founded in Boston, QuanDruPlex develops quantum-enhanced computational translational biology to improve therapeutic delivery, tissue targeting, and safety prediction before clinical development.

  • Model the context, not just the molecule

    A candidate only means something in the tissue it must reach.

  • Answer decisions, not questions

    Every engagement is scoped to a decision, with a threshold for advancing or stopping.

  • Show the reasoning

    Methods, assumptions, and limits are documented so reviewers can interrogate them.

Headquarters
Boston, Massachusetts
Partners
Academic investigators & emerging biotech
Engagement
Sponsored programs, grants, diligence

Leadership

Sai
Translational Sciences & Clinical Development
Harvard & Amgen Background
Woo-Ram Lee, PhD
Lead Quantum Scientist
Larissa Bifano, JD
Patent Counsel
Curtis Mo, JD
Corporate Counsel
Contact

Tell us what you're trying to advance.

Seven questions. No account required.

Partnerships
saik [at] quandruplex.com
Scientific inquiries
emily.carter [at] quandruplex.com
Grant collaboration
sai [at] quandruplex.com
Mailing address
100 Summer Street
Boston, Massachusetts, USA